1.Hemopericardium and Cardiac Tamponade in a Patient Treated with Dabigatran Etexilate.
Filiz KIZILIRMAK ; Haci Murat GUNES ; Ekrem GULER ; Gultekin Gunhan DEMIR ; Oguz KARACA ; Habibe Gamze CANPOLAT
Korean Circulation Journal 2016;46(1):99-101
Dabigatran etexilate is one of the new oral anticoagulants approved to reduce the risk of stroke in patients with atrial fibrillation (AF). A variety of bleeding complications with dabigatran have been reported, but reports of hemopericardium are rare. We described a case of a 66 year-old female patient with non-valvular AF receiving dabigatran etexilate 150 mg twice daily for one year who suffered from hemopericardium. Her laboratory tests performed 1 year prior were normal and her admission tests revealed acute renal failure and elevated international normalized ratio (INR) level (4.79). Urgent pericardiocentesis was followed by improved renal functions and normalized INR. Dabigatran etexilate is a new oral anticoagulant that is increasingly used in daily practice. However, life-threatening complications warrant caution. Elevated INR may be related with overdose but the association of bleeding risk of dabigatran and INR requires further confirmation.
Acute Kidney Injury
;
Anticoagulants
;
Atrial Fibrillation
;
Cardiac Tamponade*
;
Female
;
Hemorrhage
;
Humans
;
International Normalized Ratio
;
Pericardial Effusion*
;
Pericardiocentesis
;
Stroke
;
Dabigatran
2.Survival of gynecological cancers in Turkey: where are we at?.
Murat GULTEKIN ; Selin DUNDAR ; Irem KUCUKYILDIZ ; Mujdegul Zayifoglu KARACA ; Guledal BOZTAS ; Semra Hatice TURAN ; Ezgi HACIKAMILOGLU ; Bekir KESKINKILIC
Journal of Gynecologic Oncology 2017;28(6):e85-
OBJECTIVE: To investigate the 5-year relative survival rates in gynecological cancers diagnosed and treated in Turkey by year 2009 and to compare the results with developed countries. METHODS: Data of patients diagnosed for ovarian, corpus uteri or cervix uteri cancer at year 2009 are collected from 9 national cancer registry centers. Date of deaths are retracted from governmental Identity Information Sharing System (KPS). In order to calculate relative survival rates, national general population mortality tables are obtained from Turkish Statistical Institute (TurkStat). Hakulinen method is used for computing curves by R program. Data for European, Asian and some developed countries were obtained from official web pages. RESULTS: A total of 1,553 patients are evaluated. Among these, 713 (45.9%) are corpus uteri cancers, while remaining 489 (31.5%) are ovarian and 351 (22.6%) are cervix uteri. Five-year overall relative survival rates are 85%, 50%, and 62% for corpus uteri, ovarian, and cervix uteri, respectively. These figures are between 73%–87% for corpus uteri, 31%–62% for ovarian and 61%–80% for cervix uteri in developed countries. Stage is the most important factor for survival in all cancers. Five-year relative survival rates in corpus uteri cancers are 92%, 66%, and 38% for localized, regional, and distant metastatic disease, respectively. These figures are 77%, 57%, and 29% for ovarian; 80%, 50%, and 22% for cervix uteri. CONCLUSION: This is the first report from Turkey giving national overall relative survival for gynecological cancers from a population based cancer registry system.
Asian Continental Ancestry Group
;
Cervix Uteri
;
Developed Countries
;
Female
;
Genital Neoplasms, Female
;
Humans
;
Information Dissemination
;
Methods
;
Mortality
;
Ovarian Diseases
;
Survival Rate
;
Turkey*
;
Uterus